

Xspray - Narrowing The Focus

Redeye adjusts estimates and fair value range for Xspray in light of the company's change of focus to Dasynoc as its lead project, and its now exclusive targeting of improved generics. In our view, the longer-term prospects for Xspray are relatively intact, which we expect the market to realize as Dasynoc approaches launch, estimated in 2023

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Xspray - Narrowing The Focus